AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33368056 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis system (CADx) using multimodal imaging (HDWL and BLI)
Number of subjects: 60
Study 33368056 — intervention group
Group type: COMPARATOR
Intervention: Optical diagnosis by expert endoscopists
Number of subjects: 60
Study 33368056 — intervention group
Group type: COMPARATOR
Intervention: Optical diagnosis by novice endoscopists
Number of subjects: 60
Study 33368056 — intervention group
Group type: COMPARATOR
Intervention: BLI Adenoma Serrated International Classification (BASIC)
Number of subjects: 60
Study 33368142 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids
Number of subjects: 11272
Study 33368493 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal inflammation (PI)
Number of subjects: 770
Study 33368493 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal function
Number of subjects: 770
Study 33368557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with type 2 diabetes
Number of subjects: 178
Study 33368557 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women without diabetes
Number of subjects: 178
Study 33368557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with type 2 diabetes with anxiety and/or depression symptoms
Number of subjects: 178
Study 33368557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with type 2 diabetes without anxiety and/or depression symptoms
Number of subjects: 178
Study 33368569 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocytapheresis (n = 71)
Number of subjects: 125
Study 33368569 — intervention group
Group type: COMPARATOR
Intervention: Phlebotomy (n = 54)
Number of subjects: 125
Study 33368935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin treatment
Number of subjects: 0
Study 33369212 — intervention group
Group type: EXPERIMENTAL
Intervention: ST Genesia (STG-ThromboScreen and STG-DrugScreen reagents)
Number of subjects: 0
Study 33369212 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and apixaban
Number of subjects: 0
Study 33369212 — intervention group
Group type: COMPARATOR
Intervention: ST Genesia (STG-ThromboScreen)
Number of subjects: 0
Study 33369356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with epilepsy during epoch 1 (pregnancy)
Number of subjects: 351
Study 33369356 — intervention group
Group type: COMPARATOR
Intervention: Nonpregnant controls with epilepsy during epoch 1
Number of subjects: 351
Study 33369356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 351
Study 33369356 — intervention group
Group type: COMPARATOR
Intervention: Nonpregnant controls
Number of subjects: 351
Study 33369570 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored inhaled corticosteroid treatment
Number of subjects: 0
Study 33369570 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of adherence and FeNO response
Number of subjects: 0
Study 33369580 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 0
Study 33369580 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib in combination with bevacizumab
Number of subjects: 0
Study 33369580 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors (PARPi)
Number of subjects: 0
Study 33369581 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs for HER2-positive breast cancer (specific drugs not mentioned)
Number of subjects: 0
Study 33369581 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy and CDK4/6 inhibitors
Number of subjects: 0
Study 33369965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Stress Test (CST)
Number of subjects: 84
Study 33369965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridium Pad Test
Number of subjects: 84
Study 33369965 — intervention group
Group type: COMPARATOR
Intervention: Urodynamics (UDS)
Number of subjects: 84
Study 33369988 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive multimodal strategy (biopsy forceps, cytology brush, aspirating needle, triple needle cytology brush, needle-tipped cytology brush, core biopsy system, and bronchoalveolar lavage)
Number of subjects: 416
Study 33369988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid On-Site Evaluation (ROSE)
Number of subjects: 416
Study 33369988 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy forceps
Number of subjects: 416
Study 33369988 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirating needle
Number of subjects: 416
Study 33369988 — intervention group
Group type: COMPARATOR
Intervention: Restricted tool strategy (only biopsy forceps, standard cytology brush, and/or bronchoalveolar lavage)
Number of subjects: 416
Study 33369988 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive tool strategy
Number of subjects: 416
Study 33369988 — intervention group
Group type: COMPARATOR
Intervention: Restricted tool strategy
Number of subjects: 416
Study 33370024 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 294
Study 33370024 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 294
Study 33370479 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PK deficiency (n = 122)
Number of subjects: 122
Study 33370479 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly transfused patients (n = 65)
Number of subjects: 122
Study 33370479 — intervention group
Group type: EXPERIMENTAL
Intervention: Never transfused patients with PK deficiency
Number of subjects: 122
Study 33370479 — intervention group
Group type: COMPARATOR
Intervention: Matched population (n = 1220)
Number of subjects: 122
Study 33370721 — intervention group
Group type: EXPERIMENTAL
Intervention: Random messaging arm (text messaging intervention)
Number of subjects: 229
Study 33370721 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement learning arm (text messaging intervention)
Number of subjects: 229
Study 33370721 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 229
Study 33371015 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection after application of acetic acid (VIA)
Number of subjects: 450
Study 33371015 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable magnification device (Gynocular) based on the Swede score assessment
Number of subjects: 450
Study 33371015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk subtypes of human papillomavirus (HR-HPV, GeneXpert)
Number of subjects: 450
Study 33371015 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tests (VIA, Gynocular, HR-HPV)
Number of subjects: 450
Study 33371021 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed IBD cases
Number of subjects: 86
Study 33371021 — intervention group
Group type: COMPARATOR
Intervention: Non-IBD controls (sibling or second-degree relative, randomly selected individual from the same neighborhood)
Number of subjects: 86
Study 33371021 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD cases
Number of subjects: 86
Study 33371021 — intervention group
Group type: COMPARATOR
Intervention: Non-IBD controls
Number of subjects: 86
Study 33371020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 33371020 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) therapy
Number of subjects: 0
Study 33371033 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 598
Study 33371033 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 598
Study 33371033 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy (DAT)
Number of subjects: 598
Study 33371033 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding event
Number of subjects: 598
Study 33371033 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignancy
Number of subjects: 598
Study 33371044 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 inhibitor
Number of subjects: 520
Study 33371044 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Number of subjects: 520
Study 33371044 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione
Number of subjects: 520
Study 33371048 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 0
Study 33371048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse coaching
Number of subjects: 0
Study 33371048 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33371779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% IQP-0528 gel (10 mL rectal dose)
Number of subjects: 7
Study 33372102 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical governance programme
Number of subjects: 5000
Study 33372414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low gland formation and low neutrophil infiltration
Number of subjects: 50
Study 33372414 — intervention group
Group type: EXPERIMENTAL
Intervention: High gland formation and high neutrophils
Number of subjects: 50
Study 33372647 — intervention group
Group type: EXPERIMENTAL
Intervention: ANZANSI (family economic empowerment + multiple family groups)
Number of subjects: 100
Study 33372647 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 100
Study 33373024 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET) in OAC patients
Number of subjects: 1306
Study 33373359 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic stiffness measured by pulse wave velocity (PWV)
Number of subjects: 542
Study 33373359 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline aortic stiffness
Number of subjects: 542
Study 33373732 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycoside resistance testing
Number of subjects: 100
Study 33373732 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of rmtB gene
Number of subjects: 100
Study 33373732 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmid analysis
Number of subjects: 100
Study 33373868 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pembrolizumab combined with concurrent chemoradiotherapy (PPCT)
Number of subjects: 20
Study 33373873 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor (EGFR) inhibition
Number of subjects: 0
Study 33373873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inhibition of EGFR and TNF
Number of subjects: 0
Study 33373873 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs inhibiting TNF
Number of subjects: 0
Study 33374003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-dsDNA IgG2
Number of subjects: 1052
Study 33374003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-C1q IgG2
Number of subjects: 1052
Study 33374003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-ENO1 IgG2
Number of subjects: 1052
Study 33374003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H2A IgG2
Number of subjects: 1052
Study 33374003 — intervention group
Group type: EXPERIMENTAL
Intervention: SLEDAI values correlation
Number of subjects: 1052
Study 33374003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephritogenic IgG2 antibodies
Number of subjects: 1052
Study 33374007 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33376102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1803
Study 33376102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (REPRISE)
Number of subjects: 1803
Study 33376109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus treatment for 6 months at plasma concentration levels of 5-8 µg/L
Number of subjects: 4
Study 33376109 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus treatment for 6 months
Number of subjects: 4
Study 33376169 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP level (>10 mg/L) at discharge
Number of subjects: 2618
Study 33376169 — intervention group
Group type: COMPARATOR
Intervention: Low CRP level (≤10 mg/L) at discharge
Number of subjects: 2618
Study 33376179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical, functional and circulating biomarkers
Number of subjects: 0
Study 33376181 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical cannabis use
Number of subjects: 250
Study 33376186 — intervention group
Group type: EXPERIMENTAL
Intervention: Masculinising testosterone treatment
Number of subjects: 0
Study 33376186 — intervention group
Group type: COMPARATOR
Intervention: Coronary CT angiography
Number of subjects: 0
Study 33376186 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body muscle strength and power measurement
Number of subjects: 0
Study 33376186 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires for aggression and quality of life
Number of subjects: 0
Study 33376319 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily step count measurement using an activity monitor over 14 consecutive days.
Number of subjects: 417
Study 33376319 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of activity time at ≥3 METs (moderate-to-vigorous) and ≥2 METs (light-to-vigorous).
Number of subjects: 417
Study 33376319 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between physical activity (PA) and patient characteristics.
Number of subjects: 417
Study 33376319 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective reports of time spent in activities requiring ≥2 METs.
Number of subjects: 417
Study 33377125 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma dihydroceramides in triglyceride-rich very-low-density lipoprotein (VLDL)
Number of subjects: 0
Study 33377125 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of sphingolipid synthesis enzymes
Number of subjects: 0
Study 33377129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-powered arm
Number of subjects: 0
Study 33377129 — intervention group
Group type: COMPARATOR
Intervention: Physician-reported arm
Number of subjects: 0
Study 33377134 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 x CTLA-4 bispecific DART molecule (MGD019)
Number of subjects: 0
Study 33377134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination immunotherapy with antibodies directed against PD-1 and CTLA-4
Number of subjects: 0
Study 33377134 — intervention group
Group type: COMPARATOR
Intervention: Single agents (PD-1 or CTLA-4 antibodies)
Number of subjects: 0
Study 33377138 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliviado Dementia Care-Hospice Edition
Number of subjects: 83
Study 33377328 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN with DENEX™ system
Number of subjects: 16
Study 33378372 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Childbirth Checklist (SCC) and systems-focused mentorship
Number of subjects: 256
Study 33378384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ICS
Number of subjects: 55
Study 33378384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fluticasone propionate
Number of subjects: 55
Study 33378384 — intervention group
Group type: COMPARATOR
Intervention: High-dose budesonide
Number of subjects: 55
Study 33378384 — intervention group
Group type: EXPERIMENTAL
Intervention: Both low and high-dose ICS
Number of subjects: 55
Study 33378424 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 24 weeks
Number of subjects: 18
Study 33378424 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninfected, n=21)
Number of subjects: 18
Study 33378612 — intervention group
Group type: COMPARATOR
Intervention: Vedolizumab (induction phase)
Number of subjects: 51
Study 33378612 — intervention group
Group type: COMPARATOR
Intervention: Vedolizumab (maintenance phase, every 4 weeks)
Number of subjects: 51
Study 33378612 — intervention group
Group type: COMPARATOR
Intervention: Vedolizumab (maintenance phase, every 8 weeks)
Number of subjects: 51
Study 33380172 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 12-lipoxygenase oxylipin plasma concentrations in premenopausal females
Number of subjects: 0
Study 33380478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure-lowering therapy (specific details not provided)
Number of subjects: 813
Study 33380478 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed ophthalmic examinations (specific details not provided)
Number of subjects: 813
Study 33380480 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Indicators (QIs) for Cardiac Rehabilitation (CR)
Number of subjects: 165
Study 33380480 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Indicators (QIs) identified through a nationwide questionnaire survey
Number of subjects: 165
Study 33380480 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Indicators (QIs) developed by a consensus panel
Number of subjects: 165
Study 33380512 — intervention group
Group type: EXPERIMENTAL
Intervention: RHC (Right Heart Catheterization)
Number of subjects: 55
Study 33380512 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 55
Study 33380924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CHADS-BLED score in TF TAVR patients with atrial fibrillation (AF)
Number of subjects: 1329
Study 33380924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CHADS-BLED score in TF TAVR patients with AF
Number of subjects: 1329
Study 33381248 — intervention group
Group type: EXPERIMENTAL
Intervention: PacBio RS II platform
Number of subjects: 0
Study 33381248 — intervention group
Group type: COMPARATOR
Intervention: MiSeq platform
Number of subjects: 0
Study 33381755 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum neurofilament light protein
Number of subjects: 0
Study 33381769 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal tunnel decompression surgery
Number of subjects: 855832
Study 33382032 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure therapy; Treatment adherence rate: 55% at 1 year.
Number of subjects: 204
Study 33382032 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional therapy and opioids/sedative reduction; Treatment received by the rest of the patients with sleep apnea.
Number of subjects: 204
Study 33382032 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; High refusal rate for treatment.
Number of subjects: 204
Study 33382039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app (¡Hola Bebé, Adiós Diabetes!)
Number of subjects: 21
Study 33382121 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent atrial fibrillation
Number of subjects: 121
Study 33382121 — intervention group
Group type: COMPARATOR
Intervention: Decompensated CHF without permanent atrial fibrillation
Number of subjects: 121
Study 33382332 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance coping strategies
Number of subjects: 0
Study 33382332 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance coping strategies
Number of subjects: 0
Study 33382405 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated on the day of enrollment for 171 (87.7%) participants.
Number of subjects: 195
Study 33382405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreactive or indeterminate HIV antibody on the Geenius assay combined with ARCHITECT S/CO ≥10.
Number of subjects: 195
Study 33382405 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel AEHI criteria incorporating ARCHITECT S/CO.
Number of subjects: 195
Study 33382877 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D+OA
Number of subjects: 66
Study 33382877 — intervention group
Group type: EXPERIMENTAL
Intervention: CON+OA
Number of subjects: 66
Study 33382877 — intervention group
Group type: COMPARATOR
Intervention: T2D-OA
Number of subjects: 66
Study 33382877 — intervention group
Group type: COMPARATOR
Intervention: CON-OA
Number of subjects: 66
Study 33382891 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urinary 5-hydroxyindolacetic acid (24u5HIAA)
Number of subjects: 80
Study 33382891 — intervention group
Group type: EXPERIMENTAL
Intervention: overnight urinary 5HIAA (Ou5HIAA)
Number of subjects: 80
Study 33382891 — intervention group
Group type: EXPERIMENTAL
Intervention: plasmatic 5HIAA (p5HIAA)
Number of subjects: 80
Study 33382891 — intervention group
Group type: EXPERIMENTAL
Intervention: 24u5HIAA
Number of subjects: 80
Study 33382891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ou5HIAA
Number of subjects: 80
Study 33382891 — intervention group
Group type: EXPERIMENTAL
Intervention: p5HIAA
Number of subjects: 80
Study 33383007 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation using the CoreValve and Evolut R devices
Number of subjects: 202
Study 33383315 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based classification using a multi-layer deep convolutional neural network (CNN) trained on FAF images.
Number of subjects: 314
Study 33383315 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based classification using a multi-layer deep convolutional neural network (CNN) with 10-fold cross-validation.
Number of subjects: 314
Study 33383350 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of testosterone cypionate intramuscularly every 28 days concurrent with a luteinising hormone-releasing hormone agonist/antagonist
Number of subjects: 29
Study 33383350 — intervention group
Group type: EXPERIMENTAL
Intervention: bipolar androgen therapy (BAT)
Number of subjects: 29
Study 33383350 — intervention group
Group type: EXPERIMENTAL
Intervention: after progression on BAT
Number of subjects: 29
Study 33383395 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-conducted acoustic stimulation
Number of subjects: 8
Study 33383486 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 21
Study 33383646 — intervention group
Group type: EXPERIMENTAL
Intervention: ABL001 with paclitaxel
Number of subjects: 0
Study 33383646 — intervention group
Group type: EXPERIMENTAL
Intervention: ABL001 with irinotecan
Number of subjects: 0
Study 33383646 — intervention group
Group type: COMPARATOR
Intervention: ABL001
Number of subjects: 0
Study 33383646 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0
Study 33383646 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan
Number of subjects: 0
Study 33384331 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing pictures of foods
Number of subjects: 0
Study 33384331 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing food pictures
Number of subjects: 0